Kete Campbell-Coker, RGN, MSc, is a clinical research nurse and psychodynamic psychotherapist in training with a research focus on psychedelic-assisted therapies for treatment-resistant mental health conditions. She is currently the Lead Nurse and Manager at the Centre for Mental Health Research and Innovation, South London and Maudsley NHS Foundation Trust, where she oversees clinical delivery across multiple investigator-led and commercial psychedelic trials.

Her recent work has been embedded within the King’s College London Psychoactive Trials Group, contributing to several high-profile studies, including the COMPASS Pathways and PSIDER trials investigating the safety, efficacy, and therapeutic mechanisms of psilocybin in populations with major depressive disorder, anorexia nervosa, and PTSD.

Kete has played key roles in participant recruitment, trial protocol implementation, adverse event monitoring, and co-facilitation of therapeutic dosing and integration sessions. She is a co-author on a 2022 New England Journal of Medicine publication reporting on a multinational, randomised controlled trial of psilocybin for treatment-resistant depression.

With clinical training spanning critical care, complex paediatric nursing, and psychodynamic psychotherapy, her work bridges patient-facing clinical care with rigorous trial delivery.

Kete is completing an MSc in Psychodynamic Counselling and Psychotherapy at Birkbeck, University of London, and maintains a therapeutic practice at The Psychedelic Experience Clinic, where she provides psychodynamically-informed integration support.

Her research interests include relational processes in psychedelic therapy, ethical frameworks for clinical psychedelic work, and the development of integrative care models that connect biomedical and psychotherapeutic paradigms.